Omadacycline tosylate NEW
| Price | $956 |
| Package | 50mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-10-24 |
Product Details
| Product Name: Omadacycline tosylate | CAS No.: 1075240-43-5 |
| Supply Ability: 10g | Release date: 2025/10/24 |
Product Introduction
Bioactivity
| Name | Omadacycline tosylate |
| Description | Omadacycline tosylate (PTK 0796 tosylate) is an orally administered aminocyclitol antibacterial agent and tetracycline antibiotic exhibiting broad-spectrum antimicrobial activity against Gram-positive, Gram-negative, anaerobic, and atypical pathogens. Omadacycline tosylate binds to the 30S ribosomal subunit of bacteria to inhibit protein synthesis and may be employed in studies of pneumonia and cutaneous infections. |
| In vitro | The 90% minimum inhibitory concentrations (MIC₉₀) of omadacycline tosylate against methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus (VRE), and beta-hemolytic streptococci are 1.0 μg/ml, 0.25 μg/ml, and 0.5 μg/ml, respectively; its MIC₉₀ against penicillin-resistant Streptococcus pneumoniae (PRSP) and Haemophilus influenzae (H. influenzae) are 0.25 μg/ml and 2.0 μg/ml, respectively [2]. Omadacycline tosylate (10 μM, equivalent to 5.57 μg/ml) inhibits the ligand-binding activity of the M2 subtype of muscarinic acetylcholine receptors (M2 receptors) by 82%. At the same time, it exerts no substantial effect on the M3 subtype of muscarinic receptors (M3 receptors) or nicotinic acetylcholine receptors [5]. |
| In vivo | In the mouse abdominal infection model, a single intravenous injection of Omadacycline tosylate (0.11-18 mg/kg) demonstrated therapeutic effects against Streptococcus pneumoniae, Escherichia coli, and Staphylococcus vitis vinifera. The 50% effective dose (ED₅₀) for Streptococcus pneumoniae ranged from 0.45 mg/kg to 3.39 mg/kg, while the ED₅₀ for Staphylococcus vitis vinifera ranged from 0.30 mg/kg to 1.74 mg/kg. The ED₅₀ for Escherichia coli was 2.02 mg/kg[2]. |
| Storage | keep away from moisture,keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | H2O : 10 mg/mL (13.72 mM), Sonication is recommended. DMSO : Soluble |
| Keywords | Omadacycline Tosylate |
| Inhibitors Related | Neomycin sulfate | Adipic dihydrazide | Ampicillin sodium | Acetic Acid | Kanamycin sulfate | Sulfamethoxazole sodium | Terbinafine hydrochloride | Metronidazole | Copper(Ⅱ) Sulfate | Doxycycline | Trisodium Phosphate | BES |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $0.00/25kg |
VIP1Y
|
Shaanxi Dideu New Materials Co. Ltd
|
2025-06-12 | |
| $0.00/1g |
VIP2Y
|
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
|
2024-12-30 | |
| $0.00/5kg |
VIP1Y
|
Guangzhou Tosun Pharmaceutical Ltd
|
2024-12-27 | |
| $0.00/1g |
Biopole Pharmatech Co., Ltd.
|
2024-01-19 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, USA
INQUIRY